|
Double Helix | June 17 2008 |
|
In the US, healthcare consultancy Double Helix has expanded with the appointments of Pattie O’Donnell as Director / Moderator, Art McKee as SVP, and Hardoncourt ‘Trip’ Trepagnier as SVP Strategic Quantitative Research. O’Donnell joins with more than 15 years’ market research experience of working with both healthcare professionals and consumer patients. She previously worked at MR consultancy, National Analysts Worldwide, and holds a BS from Penn State University. McKee joins from Ziment. In his new role, he is responsible for new business development, utilizing his 16 years’ market research to help pharma clients build their pipelines and existing brands. He holds a BA from Rider University and an MBA from LaSalle University. Trepagnier has twenty years’ healthcare industry experience in marketing, product development and strategic planning positions. During the last six years he has served as a market research consultant, conducting custom primary research with patients and medical professionals for pharmaceutical, biotech and medical device companies. Most recently, he worked for HCD Research. Trepagnier earned a BS in Statistics from Stanford University and an MBA in marketing from the Wharton Graduate School. Commenting on these additions to the Double Helix US team, President Jim Goldenberg said: ‘These three highly talented and experienced market researchers further enhance Double Helix’ already strong custom qualitative and quantitative client focused research solutions.’ Headquartered in London, UK, with offices in the UK, Double Helix was founded in 1995 to provide pharma, bio and device clients with custom market research. Web site: www.doublehelixdevelopment.com . Last month, the firm launched Printer-friendly version of this article. Email this article to a friend.
|
|
